Previous 10 | Next 10 |
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Adaptimmune Therapeutics (NASDAQ: ADAP) , a clinical-stage biotech, saw its shares spike by as much as 10% in early morning trading Monday. Although the stock has cooled off somewhat in afternoon trading, its shares were still up by a healthy 8% as of 12:52 p.m. EDT Monday. Adap...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Adaptimmune Therapeutics plc (ADAP) Q2 2021 Earnings Conference Call August 09, 2021, 04:30 PM ET Company Participants Juli Miller - IR Adrian Rawcliffe - CEO Helen Tayton-Martin - Co-Founder and Chief Business Officer Elliot Norry - Senior VP and Chief Medical Officer John Lunger - Chief Pat...
Image source: The Motley Fool. Adaptimmune Therapeutics plc (NASDAQ: ADAP) Q2 2021 Earnings Call Aug 9, 2021 , 4:20 p.m. ET Operator Continue reading For further details see: Adaptimmune Therapeutics plc (ADAP) Q2 2021 Earnings Call Trans...
- SPEARHEAD-1 data presented at ASCO with overall response rate of 39.3% in synovial sarcoma and MRCLS; on track to file BLA for afami-cel next year - - SURPASS trial data from 23 evaluable patients to be presented at ESMO - - ADP-A2AFP Phase 1 trial data from 11 evaluable patient...
Shares have fallen significantly from peak achieved in Q3 2020. It appears that the TCR space could be ready to come of age, and there's room for multiple winners here. I found presentations by management to be refreshing (straightforward, continually improving product profile, focusi...
PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 28, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the second quarter ended June 30, 2021, after the US markets ...
Adaptimmune Therapeutics plc (NASDAQ:ADAP) traded today at a new 52-week low of $3.55. This new low was reached on below average trading volume as 263,000 shares traded hands, while the average 30-day volume is approximately 797,000 shares. There is potential upside of 1.2% for shares of...
Shares of Adaptimmune Therapeutics (NASDAQ: ADAP) , a small-cap cancer immunotherapy company, slid by a hefty 21% during the first six months of 2021, according to data from S&P Global Market Intelligence . By contrast, the biotech's shares were among the hottest in the enti...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment option for people with synovial sarcoma in more than a decade Adaptimmune to hold webcast at https://www.gowebcasti...
2024-07-30 07:30:03 ET H.C. Wainwright analyst issues BUY recommendation for ADAP on July 30, 2024 06:07AM ET. ADAP was trading at $1.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold, ...
2024-07-30 07:00:10 ET Arthur He from H.C. Wainwright issued a price target of $4.00 for ADAP on 2024-07-30 06:07:00. The adjusted price target was set to $4.00. At the time of the announcement, ADAP was trading at $1.37. The overall price target consensus is at $2.54 wi...